Compare Amylx Pharmaceuticals Inc (AMLX) vs YieldMax NVDA Option Income Strategy ETF (NVDY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs YieldMax NVDA Option Income Strategy ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while YieldMax NVDA Option Income Strategy ETF trades at $12.66. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| AMLX | NVDY | |
|---|---|---|
Market Cap | $1.98B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $18.70 | $17.96 |
52-Week Low | $7.64 | $12.03 |
Enterprise Value | $1.70B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
NVDY, the YieldMax NVDA Option Income Strategy ETF, trades at $12.75, up 2.66% today, amid a bearish technical signal. The fund generates weekly dividends from selling options on NVIDIA stock, with recent payouts ranging from $0.10 to $0.21. Key support sits at $12, resistance at $13, while RSI readings are neutral but ADX indicates a strong downtrend. News highlights focus on the trade-off between income and missing NVIDIA's upside potential.
Outlook hinges on NVIDIA's volatility sustaining option premiums, offering high yield but capped gains. Risks include underperformance if NVIDIA rallies sharply and reliance on options strategy execution. The fund appeals to income-focused investors willing to sacrifice growth for distributions, with sentiment mixed due to opportunity cost concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →
